• Biogen swung to a third-quarter 2026 GAAP diluted loss of $0.14 per share, primarily due to transaction-related charges.
• Total revenue rose 11% year over year to $2.8 billion.
• Rare disease revenue climbed 27% to $676.3 million, while multiple sclerosis revenue fell 13% to $919.3 million year over year.
• Top-line results from both Phase 3 litifilimab studies in systemic lupus erythematosus are expected in the first half of December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.